Table 3 Treatment efficacy.

From: Adding cetuximab to paclitaxel and carboplatin for first-line treatment of carcinoma of unknown primary (CUP): results of the Phase 2 AIO trial PACET-CUP

 

Arm A

(Chemo)

Arm B

(Chemo + Cet)

All patients

N = 72

N = 78

N = 150

Tumour response

PR

11

17

28

 

15%

22%

19%

95% CI:

7.9–26%

13–33%

13–26%

SD

25

25

50

PD

31

32

63

NA

5

4

9

Progression-free survival

Median

3.71

4.56

3.84

95% CI

3.04–4.37

2.89–6.22

2.90–4.77

HR

0.98

95% CI: 0.70–1.37

 

Overall survival

Median

8.13

7.38

8.13

95% CI

6.46–9.80

5.12–9.64

6.81–9.46

HR

1.10

95% CI: 0.77–1.56

 
  1. Bold values indicate statistical significance.
Back to article page